Vident Investment Advisory’s Ascendis Pharma A/S ASND Stock Holding History

Vident Investment Advisory’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,971	Closed	-$459K	–	897
2020 Q3	$459K	Sell	2,971 -7,250	-71%	-$1.04M	0.02%	686
2020 Q2	$1.51M	Buy	+10,221	New	+$1.4M	0.08%	309
2018 Q3	–	Sell	-7,785	Closed	-$518K	–	926
2018 Q2	$518K	Sell	7,785 -997	-11%	-$65.6K	0.02%	645
2018 Q1	$550K	Buy	+8,782	New	+$494K	0.02%	573

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Vident Investment Advisory's ASND Position: Q4 2020 in Review

Vident Investment Advisory sold out of Ascendis Pharma A/S (ASND) in Q4 2020, closing a stake of 2,971 shares — an estimated $459K sold.

Vident Investment Advisory first reported a position in ASND in Q1 2018 and held it in 4 quarters. The position peaked at $1.51M in Q2 2020. 173 funds tracked by Wall St. Rank hold ASND as of Q4 2020.

Vident Investment Advisory reported no remaining Ascendis Pharma A/S position as of Q4 2020 after selling out during the quarter.
Vident Investment Advisory sold 2,971 Ascendis Pharma A/S shares in Q4 2020, an estimated $459K.
Vident Investment Advisory first reported a position in Ascendis Pharma A/S in Q1 2018 and held it in 4 quarters.
Vident Investment Advisory's Ascendis Pharma A/S position peaked at $1.51M in Q2 2020.
173 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2020.

Based on Vident Investment Advisory's 13F filing for Q4 2020, filed 8 Feb 2021.